Evidence map›Paper›PMID 40000538›Full record

Observational studyBreast cancer research and treatment2025

Somatostatin receptor-targeted theranostics in patients with estrogen receptor-positive metastatic breast cancer-a prospective exploratory study.

Kunal Ramesh Chandekar, Swayamjeet Satapathy, Yamini Dharmashaktu, Sanjana Ballal, Piyush Ranjan, Atul Batra, Ajay Gogia, Sandeep Mathur, Chandrasekhar Bal

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Incidental [EJNMMI research · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kunal Ramesh ChandekarDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
Swayamjeet SatapathyDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
Yamini DharmashaktuDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sanjana BallalDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
Piyush RanjanDepartment of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, 110029, India.
Atul BatraDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Ajay GogiaDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sandeep MathurDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Chandrasekhar BalDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India. csbal@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSomatostatin receptor (SSTR) expression has been reported in estrogen receptor-positive (ER +) metastatic breast cancer (mBC) by pathology and immunohistochemistry studies. We aimed to investigate whether SSTR could be a viable target for PET imaging and potential theranostics in ER + mBC.

methodsThirty prospectively recruited patients with ER + mBC underwent PET/CT imaging with [

results[

conclusionsSSTR-targeted theranostics may represent a novel potential alternative in a subset of patients with ER + mBC. Its generalized applicability is limited by poor sensitivity for visceral metastases and significant inter-lesion heterogeneity. Future studies must identify how tumor subtype, proliferation, and prior systemic therapies impact SSTR expression levels in these patients to ensure meaningful clinical translation. CLINICAL

trial registrationClinical Trials Registry-India: CTRI/2023/03/051025 (prospectively registered on 23.03.2023).

Indexed as

Breast NeoplasmsReceptors, EstrogenReceptors, SomatostatinAdultAgedFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoplasm MetastasisOrganometallic CompoundsPositron Emission Tomography Computed TomographyProspective StudiesRadiopharmaceuticalsTheranostic NanomedicineFluorodeoxyglucose F18gallium Ga 68 dotatateOrganometallic CompoundsRadiopharmaceuticalsReceptors, EstrogenReceptors, Somatostatin[18F]FDG PET/CT[68Ga]Ga-DOTATATE PET/CTEstrogen receptor (ER)Metastatic breast cancer (mBC)Somatostatin receptor (SSTR)

Identifiers

PMID40000538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.